Deborah Hunter

6.9k total citations · 2 hit papers
54 papers, 5.1k citations indexed

About

Deborah Hunter is a scholar working on Genetics, Molecular Biology and Surgery. According to data from OpenAlex, Deborah Hunter has authored 54 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 14 papers in Molecular Biology and 11 papers in Surgery. Recurrent topics in Deborah Hunter's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers), Anesthesia and Pain Management (10 papers) and Kruppel-like factors research (7 papers). Deborah Hunter is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers), Anesthesia and Pain Management (10 papers) and Kruppel-like factors research (7 papers). Deborah Hunter collaborates with scholars based in United States, United Kingdom and Germany. Deborah Hunter's co-authors include Anthony W. Ferrante, Jacob E. Lemieux, Israel Charo, Reid Huber, Kris Vaddi, Sarah Slaymaker, Rudolph L. Leibel, Stuart P. Weisberg, Alessandro M. Vannucchi and Giovanni Barosi and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Deborah Hunter

50 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

2005 1.2k citations Stuart P. Weisberg, Deborah Hunter et al. Journal of Clinical Investigation profile →
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

2012 1.2k citations Claire Harrison, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Deborah Hunter United States	31	1.9k	1.7k	1.3k	1.1k	955	54	5.1k
Kris Vaddi United States	26	1.5k 0.8×	1.1k 0.7×	909 0.7×	701 0.7×	955 1.0×	68	3.7k
Bouke P. C. Hazenberg Netherlands	34	3.3k 1.7×	639 0.4×	462 0.4×	698 0.7×	738 0.8×	118	4.6k
José J. Fuster Spain	31	1.6k 0.9×	859 0.5×	1.2k 0.9×	960 0.9×	798 0.8×	65	4.7k
Silverio Perrotta Italy	39	1.1k 0.6×	1.9k 1.2×	1.8k 1.4×	2.0k 1.9×	229 0.2×	232	5.1k
Maria Pia Rastaldi Italy	43	2.6k 1.3×	480 0.3×	404 0.3×	394 0.4×	392 0.4×	120	7.3k
Laurence H. Beck United States	36	1.8k 0.9×	638 0.4×	718 0.6×	426 0.4×	215 0.2×	113	7.2k
Bertrand Knebelmann France	46	3.0k 1.6×	548 0.3×	729 0.6×	278 0.3×	246 0.3×	123	6.2k
Cornelius F. Waller Germany	31	867 0.4×	612 0.4×	623 0.5×	362 0.3×	339 0.4×	158	3.2k
Wenche Jy United States	41	3.0k 1.5×	265 0.2×	1.9k 1.5×	478 0.4×	399 0.4×	121	6.1k
Francesco Emma Italy	41	2.4k 1.2×	665 0.4×	353 0.3×	558 0.5×	199 0.2×	184	6.3k

Countries citing papers authored by Deborah Hunter

Since Specialization

Citations

This map shows the geographic impact of Deborah Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Hunter more than expected).

Fields of papers citing papers by Deborah Hunter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Hunter. The network helps show where Deborah Hunter may publish in the future.

Co-authorship network of co-authors of Deborah Hunter

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Hunter. A scholar is included among the top collaborators of Deborah Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Hunter. Deborah Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Talpaz, Moshe, Aaron T. Gerds, Roger M. Lyons, et al.. (2025). A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis. Leukemia Research. 155. 107732–107732.

Falchook, Gerald S., Manish R. Patel, Meredith McKean, et al.. (2023). Abstract CT172: A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced/metastatic solid tumors. Cancer Research. 83(8_Supplement). CT172–CT172. 6 indexed citations

Mascarenhas, John, Moshe Talpaz, Vikas Gupta, et al.. (2016). Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 102(2). 327–335. 86 indexed citations

Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, et al.. (2015). Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology. 33(34). 4039–4047. 237 indexed citations

Hurwitz, H., Nikhil Uppal, J. C. Bendell, et al.. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 25. ii115–ii115. 2 indexed citations

Harrison, Claire, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali, et al.. (2012). JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine. 366(9). 787–798. 1218 indexed citations breakdown →

Weisberg, Stuart P., Deborah Hunter, Reid Huber, et al.. (2005). CCR2 modulates inflammatory and metabolic effects of high-fat feeding. Journal of Clinical Investigation. 116(1). 115–124. 1226 indexed citations breakdown →

Walker, Cheryl L., Deborah Hunter, & Jeffrey I. Everitt. (2003). Uterine leiomyoma in the Eker rat: A unique model for important diseases of women. Genes Chromosomes and Cancer. 38(4). 349–356. 69 indexed citations

Finlay, Geraldine A., Deborah Hunter, Cheryl L. Walker, K. Eric Paulson, & Barry L. Fanburg. (2003). Regulation of PDGF production and ERK activation by estrogen is associated withTSC2gene expression. American Journal of Physiology-Cell Physiology. 285(2). C409–C418. 36 indexed citations

10.

Goncharova, Elena A., Dmitry A. Goncharov, Andrew Eszterhas, et al.. (2002). Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation. Journal of Biological Chemistry. 277(34). 30958–30967. 350 indexed citations

11.

Hodges-Gallagher, Leslie, Kevin D. Houston, Deborah Hunter, et al.. (2002). Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells. Molecular and Cellular Endocrinology. 196(1-2). 11–20. 30 indexed citations

12.

Astrinidis, Aristotelis, Timothy P. Cash, Deborah Hunter, et al.. (2002). Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene. 21(55). 8470–8476. 116 indexed citations

13.

Hodges-Gallagher, Leslie, et al.. (2001). An in vivo/in vitro Model to Assess Endocrine Disrupting Activity of Xenoestrogens in Uterine Leiomyoma. Annals of the New York Academy of Sciences. 948(1). 100–111. 21 indexed citations

14.

Hunter, Deborah, Leslie Hodges-Gallagher, Patricia K. Eagon, et al.. (2000). Influence of Exogenous Estrogen Receptor Ligands on Uterine Leiomyoma: Evidence from an in Vitro/in Vivo Animal Model for Uterine Fibroids. Environmental Health Perspectives. 108(s5). 829–834. 37 indexed citations

15.

Graves, Lee M., Yaqin He, John M. Lambert, et al.. (1997). An Intracellular Calcium Signal Activates p70 but Not p90 Ribosomal S6 Kinase in Liver Epithelial Cells. Journal of Biological Chemistry. 272(3). 1920–1928. 71 indexed citations

16.

Wheatley, R.G., et al.. (1995). Balanced analgesia with intravenous ketorolac and patient-controlled morphine following lower abdominal surgery. Journal of Clinical Anesthesia. 7(2). 103–108. 45 indexed citations

17.

Hunter, Deborah, et al.. (1994). Pre-emptive analgesia from intravenous administration of opioids. No effect with alfentanil.. PubMed. 49(7). 591–3. 47 indexed citations

18.

Wheatley, R.G., et al.. (1994). Extradural infusion analgesia for postoperative pain relief. British Journal of Anaesthesia. 73(4). 552–558. 32 indexed citations

19.

Madej, T.H., R.G. Wheatley, Ian Jackson, & Deborah Hunter. (1992). HYPOXAEMIA AND PAIN RELIEF AFTER LOWER ABDOMINAL SURGERY: COMPARISON OF EXTRADURAL AND PATIENT-CONTROLLED ANALGESIA. British Journal of Anaesthesia. 69(6). 554–557. 33 indexed citations

20.

Hunter, Deborah. (1991). Pain control. Relief through teamwork.. PubMed. 87(17). 35–6, 38. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact